I have a different opinion to about the appropriateness of the...

I have a different opinion to about the appropriateness of the reporting of the results here than offered by davidsite.

To me it looked pretty clean. There are very few hard and fast rules for reporting pre-clinical data – the main thing is it is reported transparently. Which is was. The mistake is thinking you apply confirmatory statistical approaches in exploratory studies. You don't .. and no-one does.

Imo one of the first things investors should look for is whether the investigators have allowed their names to be associated with the release.

In this case Steven Mutsaers provides a carefully written, balanced opinion about things.

Always look for this … when a company releases trial results and the investigators go MIA (RAP is a recent example) run away quickly.

So yep the results are not what people might have hoping for. But this is a different  issue to questioning the legitimacy of how the researchers have presented their data.

Purely for entertainment – the all-time funniest cancer vaccine mouse results ever presented from an ASX biotech?

Solbec and Mouse M5.

https://web.archive.org/web/20080828212545/http://www.cosmosmagazine.com/node/471

Sort of miss those days where one good mouse could transfer millions of dollars from the pockets of the gullible to the lucky.